PEGBIO CO-B (02565) announced that a research abstract related to its self-developed innovative candidate product, CR059, has been accepted by the American Diabetes Association (ADA) for its 2026 Scientific Sessions. The abstract has been selected as a Late Breaking Abstract and will be presented in poster format. The abstract is titled: "CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys." CR059 is an innovative candidate product independently developed by the group. According to relevant research results, CR059 has demonstrated significant weight loss effects, outstanding glucose-lowering performance, and long-term expression characteristics, showing potential as a long-acting treatment for metabolic diseases. The abstract also indicates that, based on the circRNA-LNP technology platform, CR059 has the potential to be administered monthly or even quarterly, supporting sustained expression and long-term metabolic control. The ADA Scientific Sessions is an internationally influential academic conference in the fields of diabetes and metabolic diseases. The Board believes that the acceptance and selection of the CR059 research abstract as a Late Breaking Abstract reflects the international academic community's attention to the group's latest progress in innovative research for metabolic diseases. This is expected to enhance the international academic influence of the CR059 project and strengthen market recognition of the group's innovative R&D capabilities and the value of its technology platform. According to the conference schedule, the aforementioned research abstract will be presented as a poster during the ADA 2026 Scientific Sessions.